For US Healthcare Professionals Only
Publications
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.
*Includes seizure clusters and acute or prolonged seizures
189 result(s)
phase
3
FINTEPLA® (fenfluramine)
Dravet Syndrome, Lennox-Gastaut Syndrome
Comprehensive scoping review of fenfluramine's role in managing generalized tonic-clonic seizures in developmental and epileptic encephalopathies
phase
3
BIMZELX® (bimekizumab-bkzx)
Hidradenitis Suppurativa
Efficacy and safety of Bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomized, double-blind, placebo-controlled, multicenter phase 3 trials.
phase
3
BIMZELX® (bimekizumab-bkzx)
Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
phase
3
FINTEPLA® (fenfluramine)
Lennox-Gastaut Syndrome
Correction to "Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study"
phase
3
BIMZELX® (bimekizumab-bkzx)
Psoriatic Arthritis
Effect of Bimekizumab on Patient-Reported Disease Impact in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies
phase
3
CIMZIA® (certolizumab pegol)
Non-radiographic Axial Spondyloarthritis
Long-term clinical outcomes of certolizumab pegol treatment in patients with active non‑radiographic axial spondyloarthritis stratified by baseline MRI and C‑reactive protein status
phase
4/RWE
BIMZELX® (bimekizumab-bkzx)
Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
The Cost-Effectiveness of a Bimekizumab Versus IL-17A Inhibitors Treatment-Pathway in Patients with Active Axial Spondyloarthritis in Scotland
phase
3
RYSTIGGO® (rozanolixizumab-noli)
Generalized Myasthenia Gravis
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study